Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021? By Adam Barkay|2021-06-25T06:41:37+00:00June 22nd, 2021|All, EHA 2021|Comments Off on Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021? Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: Adam Barkay Related Posts Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Prof. Florent Malard- The First microbiota therapy approved by the US FDA Prof. Florent Malard- The First microbiota therapy approved by the US FDA Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure Prof. Marion Subklewe- T-cell exhaustion induced by continuous bispecific molecule exposure Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Dr. Eolia Brissot – Positive opinion of the CHMP on tabelecleucel for the treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
